Search Results - "KHUSHALANI, N. I"

Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy by Ahmed, K.A., Abuodeh, Y.A., Echevarria, M.I., Arrington, J.A., Stallworth, D.G., Hogue, C., Naghavi, A.O., Kim, S., Kim, Y., Patel, B.G., Sarangkasiri, S., Johnstone, P.A.S., Sahebjam, S., Khushalani, N.I., Forsyth, P.A., Harrison, L.B., Yu, M., Etame, A.B., Caudell, J.J.

“…Novel targeted and immunotherapeutic agents have revolutionized systemic melanoma management. We note differing rates of distant brain control as well as…”
Get full text

Efficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis by Hamid, O., Ribas, A., Daud, A., Butler, M.O., Carlino, M.S., Hwu, W.-J., Long, G.V., Ancell, K., Hodi, F.S., Khushalani, N.I., Blank, C.U., Loquai, C., Lin, J., Diede, S.J., Robert, C.

Get full text

Respiratory syncytial virus infection in the late bone marrow transplant period : report of three cases and review by KHUSHALANI, N. I, BAKRI, F. G, CZUCZMAN, M. S, SEGAL, B. H, MCCARTHY, P. L, WENTLING, D, BROWN, K, MOHR, A, ANDERSON, B, KEESLER, C, BALL, D, BERNSTEIN, Z. P, BERNSTEIN, S. H

“…Respiratory syncytial virus (RSV) infection is an important cause of respiratory mortality in immunosuppressed patients, including bone marrow transplant (BMT)…”
Get full text

NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM) by Moschos, S.J., Eroglu, Z., Khushalani, N.I., Kendra, K.L., Ansstas, G., In, G.K., Wang, P., Liu, G., Collichio, F.A., Arrowood, C.C., Reed, J.E., Garrett-Mead, N., Thomas, N.E., Ollila, D.W., Ivy, S.P., Ivanova, A., Dees, E.C., Abbruzzese, J.L.

Get full text

Expression of Genes Related to Activity of Oxaliplatin and 5-Fluorouracil in Endoscopic Biopsies of Primary Esophageal Cancer in Patients Receiving Oxaliplatin, 5-Flourouracil and Radiation: Characterization and Exploratory Analysis with Survival by Leichman, L., Lawrence, D., Leichman, C.G., Nava, H., Nava, E., Proulx, G., Clark, K., Khushalani, N.I., Berdzik, J., Greco, W., Smith, P., Creaven, P.J., Kepner, J.L., Javle, M.M., Pendyala, L.

“…With a goal of identifying relations between gene expression and response (mucosal or pathological) or survival in esophageal cancer patients (stages II to IV)…”
Get full text

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma by Migden, Michael R, Rischin, Danny, Schmults, Chrysalyne D, Guminski, Alexander, Hauschild, Axel, Lewis, Karl D, Chung, Christine H, Hernandez-Aya, Leonel, Lim, Annette M, Chang, Anne Lynn S, Rabinowits, Guilherme, Thai, Alesha A, Dunn, Lara A, Hughes, Brett G.M, Khushalani, Nikhil I, Modi, Badri, Schadendorf, Dirk, Gao, Bo, Seebach, Frank, Li, Siyu, Li, Jingjin, Mathias, Melissa, Booth, Jocelyn, Mohan, Kosalai, Stankevich, Elizabeth, Babiker, Hani M, Brana, Irene, Gil-Martin, Marta, Homsi, Jade, Johnson, Melissa L, Moreno, Victor, Niu, Jiaxin, Owonikoko, Taofeek K, Papadopoulos, Kyriakos P, Yancopoulos, George D, Lowy, Israel, Fury, Matthew G

“…Among patients with advanced cutaneous squamous-cell carcinoma, the PD-1 inhibitor cemiplimab induced a response in approximately half the patients and was…”
Get full text

P14.26 Leptomeningeal Disease Secondary to Melanoma: Diagnosis, Treatment, and Outcomes at a Single Institution between 2013 and 2019 by Pina, Y, Mokhtari, S, Evernden, B R, Tran, N D, Smalley, I, Khushalani, N I, Law, V W, Puskas, J A, Caceres, G, Smalley, K, Peguero, E, Forsyth, P

“…Abstract BACKGROUND Leptomeningeal disease (LMD) is devastating with a median survival of only 8–10 weeks. LMD affects approximately 5% to 25% of melanoma…”
Get full text

1321PA phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary report by Kim, S, Khushalani, N I, Eroglu, Z, Russell, J, Wuthrick, E, Caudell, J, Harrison, L, Aoki, M, Shah, H, Blakaj, D, Markowitz, J, Chen, D-T, Messina, J, Rose, T, Tsai, K, Brohl, A S

“…Abstract Background MCC is an aggressive cutaneous malignancy. Though checkpoint inhibitor therapy has dramatically improved the treatment landscape, outcome…”
Get full text

1248PDEfficacy of pembrolizumab (Pembro) in patients (Pts) with advanced melanoma with stable brain metastases (BM) at baseline: A pooled retrospective analysis by Hamid, O, Ribas, A, Daud, A, Butler, M O, Carlino, M S, Hwu, W-J, Long, G V, Ancell, K, Hodi, F S, Khushalani, N I, Blank, C U, Loquai, C, Lin, J, Diede, S J, Robert, C

Get full text

1318PPhase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC) by Rischin, D, Lim, A M, Schmults, C D, Khushalani, N I, Hughes, B G, Schadendorf, D, Dunn, L A, Chang, A L S, Hauschild, A, Ulrich, C, Eigentler, T, Migden, M R, Pavlick, A C, Geiger, J, Stankevich, E, Li, S, Lowy, I, Fury, M G, Guminski, A

“…Abstract Background Cemiplimab-rwlc is the only US FDA-approved treatment for patients (pts) with advanced CSCC. The primary analysis of a weight-based regimen…”
Get full text

1268PNCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM) by Moschos, S J, Eroglu, Z, Khushalani, N I, Kendra, K L, Ansstas, G, In, G K, Wang, P, Liu, G, Collichio, F A, Arrowood, C C, Reed, J E, Garrett-Mead, N, Thomas, N E, Ollila, D W, Ivy, S P, Ivanova, A, Dees, E C, Abbruzzese, J L

Get full text

Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection by Eroglu, Zeynep, Broman, Kristy K, Thompson, John F, Nijhuis, Amanda, Hieken, Tina J, Kottschade, Lisa, Farma, Jeffrey M, Hotz, Meghan, Deneve, Jeremiah, Fleming, Martin, Bartlett, Edmund K, Sharma, Avinash, Dossett, Lesly, Hughes, Tasha, Gyorki, David E, Downs, Jennifer, Karakousis, Giorgos, Song, Yun, Lee, Ann, Berman, Russell S, van Akkooi, Alexander, Stahlie, Emma, Han, Dale, Vetto, John, Beasley, Georgia, Farrow, Norma E, Hui, Jane Yuet Ching, Moncrieff, Marc, Nobes, Jenny, Baecher, Kirsten, Perez, Matthew, Lowe, Michael, Ollila, David W, Collichio, Frances A, Bagge, Roger Olofsson, Mattsson, Jan, Kroon, Hidde M, Chai, Harvey, Teras, Jyri, Sun, James, Carr, Michael J, Tandon, Ankita, Babacan, Nalan Akgul, Kim, Younchul, Naqvi, Mahrukh, Zager, Jonathan, Khushalani, Nikhil I

“…Until recently, most patients with sentinel lymph node-positive (SLN+) melanoma underwent a completion lymph node dissection (CLND), as mandated in published…”
Get full text

Phase I study of sunitinib with irinotecan/5-fluorouracil/ leucovorin (FOLFIRI) for advanced gastroesophageal cancers by Khushalani, N. I., Fetterly, G. J., Iyer, R. V., Litwin, A., Brady, W., Javle, M. M.

“…Abstract only…”
Get full text

Brain metastases in esophageal carcinoma by Saadah, K., Miller, A., Prasad, D., Yang, G., Bellavia, T., Iyer, R. V., Khushalani, N. I.

“…Abstract only…”
Get full text

Response-based outcomes in patients with esophageal cancer treated with primarily non-cisplatin and 5-fluorouracil–based trimodality therapy by Malik, N. K., Warren, G. W., Yang, G., Zeeck, K., Papsidero, T., Patil, S., Khushalani, N. I., Sher, T., Yendamuri, S. S., Nava, H. R., Salerno May, K.

“…Abstract only…”
Get full text

The effect of smoking history on response and survival outcomes patients with in esophageal cancer treated with neoadjuvant concurrent chemoradiotherapy followed by surgery by Salerno May, K., Malik, N. K., Yang, G., Patil, S., Flaherty, L., Khushalani, N. I., Sher, T., Yendamuri, S. S., Nava, H. R., Warren, G. W.

“…Abstract only…”
Get full text

Phase II multicenter study of erlotinib with radiation therapy (RT) for elderly patients (pts) with esophageal carcinoma (EC): Final report by Iyer, R. V., Yang, G., Schefter, T. E., Tan, W., Nava, H. R., Levea, C., Litwin, A., Robins, M., Khushalani, N. I.

“…Abstract only 135 Background: Elderly pts with comorbidities have limited Rx options for localized EC. High EGFR expression correlates with poor response to…”
Get full text

Gene expression profile (GEP) for the prediction of pathologic complete response (pCR): Preliminary data from a neoadjuvant study of capecitabine (C), oxaliplatin (OXP), and radiation (RT) for esophageal cancer (EC) by Khushalani, N. I., Yang, G., Tan, W., Miecznikowski, J., Wang, D., Iyer, R. V., Yendamuri, S. S., Nwogu, C. E., Nava, H. R., Javle, M. M.

“…Abstract only…”
Get full text

Renal atrophy secondary to chemoradiation treatment of abdominal malignancies by Salerrno May, K. S., Yang, G. Y., Iyer, R. V., Chandrasekhar, R., Wilding, G., Khushalani, N. I., Yendamuri, S. S., Gibbs, J. F., Fakih, M.

“…Abstract only e15532 Background: Information on renal atrophy following abdominal chemoradiation (CRT) is limited. Methods: Patients who received concurrent…”
Get full text

Capecitabine (C), oxaliplatin (OXP), and radiation (RT) in resectable esophagus cancer (EC): A phase II trial with gene expression profiling (GEP) by Khushalani, N. I., Miecznikowski, J., Wang, D., Nowak, N., Nava, H., Nava, M. E., Tan, W., Iyer, R., Yang, G., Pendyala, L.

“…Abstract only e15543 Background: Novel chemotherapy regimens in combination with RT aim to improve the pathologic complete response (pCR) in EC. Following our…”
Get full text